With the emergence of the anabolic therapies, such as romosozumab which inhibits sclerostin, complications of discontinuing anti‐resorptive therapy, as well as an aging population and increased prevalence of osteoporosis, attention in the field has turned to how to best utilize these agents over a long period of time for optimal bone mass gain and reduced fracture risk. This evidence concerns the gene SOST and osteoporosis.